FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:90-94 January 5, 2006 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Baden, L. R. Related Article by Bucaneve, G. Related Article by Cullen, M. PubMed Citation

To the Editor: The recent studies by Bucaneve et al.¹ and Cullen et al.² (Sept. 8 issue) suggest that many patients with cancer and neutropenia may benefit from levofloxacin prophylaxis. Although the reports were published in tandem, their clinical implications differ fundamentally. Bucaneve et al. targeted "high-risk" patients (stem-cell transplant recipients or patients with leukemia) with anticipated neutropenia lasting more than seven days, a previously accepted approach.³

In contrast, most patients studied by Cullen et al. had solid tumors. Because patients with such tumors are unlikely to have prolonged or profound neutropenia, they are at lower risk for infectious complications.⁴ . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.